Priority review is another FDA program that aims to shorten the review period for drugs that offer significant improvements in the treatment, diagnosis, or prevention of serious conditions. The review period is reduced from the standard 10 months to 6 months. Priority review can be critical in epidemiological studies where timely access to effective treatments can significantly affect public health outcomes.
